Doctor of Osteopathy Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Gavin Little

Internal Medicine Stratham, NH Doctor of Osteopathy

NPI 1598792004 CMS profile 163539

118 Portsmouth Ave Bldg D, Suite C, Stratham, NH 03885

Open in the dashboard

General payments

$5,503

349 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Gavin Little of Stratham, NH is reported in the CMS Open Payments database as having received $5,503 across 349 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $1,744 99
2020 General $1,719 110
2019 General $2,040 140

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gavin Little
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gavin Little were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gavin Little Internal Medicine median Middle half National median
2019 $2,040 $159 $48–$570 $163
2020 $1,719 $119 $33–$402 $114
2021 $1,744 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Pfizer Inc. $990 68 payments
  2. AstraZeneca Pharmaceuticals LP $620 37 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $520 31 payments
  4. Lilly USA, LLC $437 34 payments
  5. GlaxoSmithKline, LLC. $405 25 payments
  6. Merck Sharp & Dohme Corporation $247 15 payments
  7. Astellas Pharma US Inc $229 11 payments
  8. Allergan Inc. $202 15 payments
  9. Novo Nordisk Inc $202 15 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $188 12 payments
  11. Other $1,463 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $5,335 342 payments
  2. Education $168 7 payments
Products named General payments · program years 2019–2021
  1. ELIQUIS $530 33 payments
  2. CHANTIX Neuroscience;Tobacco Dependence $389 24 payments
  3. CHANTIX Neuroscience;Tobacco Dependence $310 24 payments
  4. COLOGUARD $270 23 payments
  5. JANUVIA $247 15 payments
  6. TRELEGY ELLIPTA $245 14 payments
  7. SPIRIVA RESPIMAT $242 16 payments
  8. JARDIANCE $207 17 payments
  9. TRULICITY $195 17 payments
  10. XIFAXAN $188 12 payments
  11. Other $4,901 313 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 64 drugs

Part D claims

2,338

Median for Internal Medicine: 777

Drug cost

$174,885

Median for Internal Medicine: $73,373

Branded share of claims

15.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 43 $59,393
Eliquis Apixaban Brand 37 $47,103
Xarelto Rivaroxaban Brand 12 $17,407
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $15,494
Symbicort Budesonide/Formoterol Fumarate Brand 17 $3,918
Atorvastatin Calcium Generic 246 $2,594
Aripiprazole Generic 13 $2,255
Levothyroxine Sodium Generic 142 $1,982
Synthroid Levothyroxine Sodium Brand 17 $1,925
Valsartan Generic 31 $1,897

The 10 drugs with the highest cost, of 64 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$66,587

Of which drugs: $914

Medicare patients

375

Average age 74

Services billed

1,697

200 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 40%
Diabetes 20%
Ischemic heart disease 18%
Atrial fibrillation 17%
Depression 17%
Chronic kidney disease 16%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 11 11 $890

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record